ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

TNYA Tenaya Therapeutics Inc

4,68
0,12 (2,63%)
Après les heures de négociation
Dernière mise à jour : 23:16:11
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Tenaya Therapeutics Inc TNYA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,12 2,63% 4,68 23:16:11
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,58 4,47 4,81 4,68 4,56
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/3/202421:05GLOBETenaya Therapeutics Reports Fourth Quarter and Full Year..
18/3/202413:30GLOBETenaya Therapeutics Announces Publication of TN-401 Gene..
28/2/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:30GLOBETenaya Therapeutics to Participate in Upcoming March..
26/2/202414:30GLOBETenaya Therapeutics Announces Publication of Preclinical..
17/2/202402:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202402:13EDGAR2Form 144 - Report of proposed sale of securities
08/2/202423:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202414:15EDGAR2Form 8-K - Current report
08/2/202414:00GLOBETenaya Therapeutics Announces Pricing of Underwritten..
31/1/202422:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/1/202414:30GLOBETenaya Therapeutics to Participate at the 42nd Annual J.P...
21/11/202322:30GLOBETenaya Therapeutics to Participate at the 35th Annual Piper..
08/11/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12EDGAR2Form 8-K - Current report
08/11/202322:05GLOBETenaya Therapeutics Reports Third Quarter 2023 Financial..
26/10/202314:30GLOBETenaya Therapeutics Announces FDA Clearance to Begin..
09/10/202314:30GLOBETenaya Therapeutics Presents Encouraging New Clinical and..
05/10/202314:30GLOBETenaya Therapeutics Doses First Patient in the MyPeak-1™..
02/10/202323:30GLOBETenaya Therapeutics Publishes Preclinical Data in..
21/9/202322:05GLOBETenaya Therapeutics to Present Data for TN-301 and TN-201 at..
31/8/202322:05GLOBETenaya Therapeutics to Participate at the 21st Annual Morgan..
19/8/202300:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/8/202303:10EDGAR2Form 144 - Report of proposed sale of securities
09/8/202322:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:19EDGAR2Form 8-K - Current report
09/8/202322:05GLOBETenaya Therapeutics Reports Second Quarter 2023 Financial..
02/8/202322:05GLOBETenaya Therapeutics to Participate at the 43rd Annual..
10/5/202322:19GLOBETenaya Therapeutics Reports First Quarter 2023 Financial..
03/5/202314:00GLOBETenaya Highlights Growing Capabilities in AAV Manufacturing,..
02/5/202314:43DJNTenaya Therapeutics Gets FDA Fast-Track Designation for..
02/5/202313:50GLOBETenaya Therapeutics Receives FDA Fast Track Designation for..

Dernières Valeurs Consultées

Delayed Upgrade Clock